Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Tadalafil Improves Haemodynamics and Arterial Stiffness but Not Flow- Mediated Dilation in Grade 1 Obesity. A Single-dose, Placebo-controlled Clinical Trial

Author(s): Mariana Larios-Cárdenas, Oscar I. González-Radillo, Jhonatan Trujillo-Quirós, David Cardona-Müller, Marycruz Barocio-Pantoja, Ernesto G. Cardona-Muñoz and Fernando Grover-Páez*

Volume 20, Issue 6, 2022

Published on: 04 October, 2022

Page: [527 - 533] Pages: 7

DOI: 10.2174/1570161120666220827154417

Price: $65

Abstract

Objective: Obesity, a major health issue worldwide, is associated with increased cardiovascular risk, endothelial dysfunction, and arterial stiffness. Tadalafil has been demonstrated to improve vascular parameters.

Aim: To evaluate the effect of a single 20 mg dose of tadalafil on flow-mediated dilation and hemodynamic and arterial stiffness markers.

Methods: A randomized, double-blind, placebo-controlled study was conducted on 80 participants (41 assigned to placebo and 39 to tadalafil) with grade 1 obesity, to evaluate the acute effect of a single dose of 20 mg of tadalafil on flow-mediated dilation and hemodynamic and arterial stiffness markers.

Results: Tadalafil did not modify flow-mediated dilation. However, it significantly lowered systolic blood pressure (SBP) (130.6±17.1 vs. 125.0±12.7 mmHg, p=0.011), diastolic blood pressure (82.7±18.2 vs. 76.5±11.8 mmHg, p≤0.001), central systolic blood pressure (116.33±19.16 vs. 109.90±15.05 mmHg, p=0.001), the augmentation index (69.1±17.1 vs. 65.7±14.4, p=0.012), and brachial-ankle pulse wave velocity (1229.7±218.4 vs. 1164.0±181.7, p=0.001).

Conclusion: A single dose of tadalafil did not modify flow-mediated dilation in patients with grade 1 obesity but improved blood pressure and brachial-ankle pulse wave velocity.

Keywords: Tadalafil, PDE5i, flow-mediated dilation, arterial stiffness, nitric oxide, endothelium, obesity.

« Previous Next »
Graphical Abstract

[1]
Vecchié A, Dallegri F, Carbone F, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med 2018; 48: 6-17.
[http://dx.doi.org/10.1016/j.ejim.2017.10.020] [PMID: 29100895]
[2]
Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014; 56(4): 369-81.
[http://dx.doi.org/10.1016/j.pcad.2013.10.016] [PMID: 24438728]
[3]
Lapointe A, Piché MÈ, Weisnagel SJ, Bergeron J, Lemieux S. Associations between circulating free fatty acids, visceral adipose tissue accu-mulation, and insulin sensitivity in postmenopausal women. Metabolism 2009; 58(2): 180-5.
[http://dx.doi.org/10.1016/j.metabol.2008.09.011] [PMID: 19154950]
[4]
Virdis A. Endothelial dysfunction in obesity: Role of inflammation. High Blood Press Cardiovasc Prev 2016; 23(2): 83-5.
[http://dx.doi.org/10.1007/s40292-016-0133-8] [PMID: 27000854]
[5]
Lima Júnior JC, Moura-Assis A, Cintra RM, Quinaglia T, Velloso LA, Sposito AC. Central role of obesity in endothelial cell dysfunction and cardiovascular risk. Rev Assoc Med Bras 2019; 65(1): 87-97.
[http://dx.doi.org/10.1590/1806-9282.65.1.87] [PMID: 30758424]
[6]
Engin A. Endothelial dysfunction in obesity. Adv Exp Med Biol 2017; 960: 345-79.
[http://dx.doi.org/10.1007/978-3-319-48382-5_15] [PMID: 28585207]
[7]
Virdis A, Masi S, Colucci R, et al. Microvascular endothelial dysfunction in patients with obesity. Curr Hypertens Rep 2019; 21(4): 32.
[http://dx.doi.org/10.1007/s11906-019-0930-2] [PMID: 30949772]
[8]
Bhatta A, Yao L, Xu Z, et al. Obesity-induced vascular dysfunction and arterial stiffening requires endothelial cell arginase 1. Cardiovasc Res 2017; 113(13): 1664-76.
[http://dx.doi.org/10.1093/cvr/cvx164] [PMID: 29048462]
[9]
Quinn U, Tomlinson LA, Cockcroft JR. Arterial stiffness. JRSM Cardiovasc Dis 2012; 1(6): 1-8.
[http://dx.doi.org/10.1258/cvd.2012.012024] [PMID: 24175072]
[10]
Gavish B, Izzo JL Jr. Arterial stiffness: Going a step beyond. Am J Hypertens 2016; 29(11): 1223-33.
[http://dx.doi.org/10.1093/ajh/hpw061] [PMID: 27405964]
[11]
Peng Z, Yang L, Dong Q, Wei Q, Liu L, Yang B. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erec-tile dysfunction: A systematic review and meta-analyses. Urol Int 2017; 99(3): 343-52.
[http://dx.doi.org/10.1159/000477496] [PMID: 28628914]
[12]
Frajese GV, Pozzi F, Frajese G. Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. Clin Interv Aging 2006; 1(4): 439-49.
[http://dx.doi.org/10.2147/ciia.2006.1.4.439] [PMID: 18046921]
[13]
Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunc-tion and cardiovascular disease. Cardiol Rev 2007; 15(2): 76-86.
[http://dx.doi.org/10.1097/01.crd.0000233904.77128.49] [PMID: 17303994]
[14]
Kimura M, Higashi Y, Hara K, et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003; 41(5): 1106-10.
[http://dx.doi.org/10.1161/01.HYP.0000068202.42431.CC] [PMID: 12695418]
[15]
Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilata-tion in type 2 diabetes. Diabetes Care 2002; 25(8): 1336-9.
[http://dx.doi.org/10.2337/diacare.25.8.1336] [PMID: 12145231]
[16]
Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36(3): 845-51.
[http://dx.doi.org/10.1016/S0735-1097(00)00790-7] [PMID: 10987609]
[17]
Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA. Measured and estimated glomerular filtration rate: Current status and future direc-tions. Nat Rev Nephrol 2020; 16(1): 51-64.
[http://dx.doi.org/10.1038/s41581-019-0191-y] [PMID: 31527790]
[18]
Tomiyama H, Matsumoto C, Yamada J, et al. The relationships of cardiovascular disease risk factors to flow-mediated dilatation in Japanese subjects free of cardiovascular disease. Hypertens Res 2008; 31(11): 2019-25.
[http://dx.doi.org/10.1291/hypres.31.2019] [PMID: 19098373]
[19]
Kohara K, Tabara Y, Oshiumi A, Miyawaki Y, Kobayashi T, Miki T. Radial augmentation index: A useful and easily obtainable parameter for vascular aging. Am J Hypertens 2005; 18(1 Pt 2): 11-4.
[http://dx.doi.org/10.1016/j.amjhyper.2004.10.010] [PMID: 15683726]
[20]
Cui R, Yamagishi K, Muraki I, et al. Association between markers of arterial stiffness and atrial fibrillation in the circulatory risk in commu-nities study (CIRCS). Atherosclerosis 2017; 263: 244-8.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.918] [PMID: 28683363]
[21]
Cheng YB, Li Y, Sheng CS, Huang QF, Wang JG. Quantification of the interrelationship between brachial-ankle and carotid-femoral pulse wave velocity in a workplace population. Pulse (Basel) 2015; 3(3-4): 253-62.
[http://dx.doi.org/10.1159/000444645] [PMID: 27195246]
[22]
Jeyaseelan L, Rao PS. Methods of determining sample sizes in clinical trials. Indian Pediatr 1989; 26(2): 115-21.
[PMID: 2753525]
[23]
Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47(2): 214-22.
[http://dx.doi.org/10.1016/j.eururo.2004.10.002] [PMID: 15661417]
[24]
Özbek K, Ceyhan K, Koç F, et al. The protective effect of single dose tadalafil in contrast-induced nephropathy: An experimental study. Anatol J Cardiol 2015; 15(4): 306-10.
[http://dx.doi.org/10.5152/akd.2014.5380] [PMID: 25880289]
[25]
Pattanaik S, Kaundal P, Mavuduru RS, Singh SK, Mandal AK. Endothelial dysfunction in patients with erectile dysfunction: A double-blind, randomized-control trial using tadalafil. Sex Med 2019; 7(1): 41-7.
[http://dx.doi.org/10.1016/j.esxm.2018.11.008] [PMID: 30638829]
[26]
Ortiz Segura MC, del Río Navarro BE, Rodríguez Espino BA, et al. Abnormality of adipokines and endothelial dysfunction in Mexican obese adolescents with insulin resistance. Endocr Res 2017; 42(3): 1-8.
[http://dx.doi.org/10.1080/07435800.2017.1294601] [PMID: 28318332]
[27]
Aversa A, Fittipaldi S, Francomano D, et al. Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: In vivo and in vitro characterization. Endocrine 2017; 56(3): 639-48.
[http://dx.doi.org/10.1007/s12020-016-1208-y] [PMID: 28133708]
[28]
Young JM, Feldman RA, Auerbach SM, et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl 2005; 26(3): 310-8.
[http://dx.doi.org/10.2164/jandrol.04126] [PMID: 15866997]
[29]
Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in essential hypertension. Curr Hypertens Rep 2008; 10(1): 52-7.
[http://dx.doi.org/10.1007/s11906-008-0011-4] [PMID: 18367027]
[30]
Reffelmann T, Kloner R. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 2006; 12(27): 3485-94.
[http://dx.doi.org/10.2174/138161206778343073] [PMID: 17017941]
[31]
Kukreja RC. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Pharmacol 2007; 150(5): 538-40.
[http://dx.doi.org/10.1038/sj.bjp.0707132] [PMID: 17245364]
[32]
Gismondi RA, Oigman W, Neves MF. Antihypertensive agents and arterial stiffness. J Thorac Dis 2016; 8(7): 1386-7.
[http://dx.doi.org/10.21037/jtd.2016.05.60] [PMID: 27501534]
[33]
Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension 2003; 41(2): 297-301.
[http://dx.doi.org/10.1161/01.HYP.0000049622.07021.4F] [PMID: 12574098]
[34]
Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, et al. Beneficial effect of vardenafil on aortic stiffness and wave reflections. J Clin Pharmacol 2012; 52(8): 1215-21.
[http://dx.doi.org/10.1177/0091270011413586] [PMID: 21953573]
[35]
Özdabakoğlu O, Güllülü S, Sağ S, et al. Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: Acute effects of phosphodiesterase-5 inhibitor tadalafil. Int J Impot Res 2017; 29(3): 96-100.
[http://dx.doi.org/10.1038/ijir.2016.47] [PMID: 27928151]

Rights & Permissions Print Cite
Article Metrics
25
2
© 2024 Bentham Science Publishers | Privacy Policy